NASDAQ:LTRN Lantern Pharma (LTRN) Stock Price, News & Analysis $4.58 +0.04 (+0.88%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$4.54▼$4.8850-Day Range$3.91▼$6.4652-Week Range$2.38▼$11.99Volume22,814 shsAverage Volume49,174 shsMarket Capitalization$49.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Lantern Pharma alerts: Email Address Lantern Pharma MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy3.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingSelling Shares$62,500 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.23) to ($2.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.19 out of 5 starsMedical Sector768th out of 936 stocksPharmaceutical Preparations Industry356th out of 436 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Lantern Pharma.Read more about Lantern Pharma's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.06% of the float of Lantern Pharma has been sold short.Short Interest Ratio / Days to CoverLantern Pharma has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lantern Pharma has recently decreased by 21.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLantern Pharma does not currently pay a dividend.Dividend GrowthLantern Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LTRN. Previous Next 3.6 News and Social Media Coverage News SentimentLantern Pharma has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lantern Pharma this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for LTRN on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows1 people have added Lantern Pharma to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lantern Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $62,500.00 in company stock.Percentage Held by InsidersOnly 6.92% of the stock of Lantern Pharma is held by insiders.Percentage Held by InstitutionsOnly 28.62% of the stock of Lantern Pharma is held by institutions.Read more about Lantern Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lantern Pharma are expected to grow in the coming year, from ($2.23) to ($2.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantern Pharma is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantern Pharma is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLantern Pharma has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Lantern Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."Click here now to watch this exclusive interview About Lantern Pharma Stock (NASDAQ:LTRN)Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Read More LTRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LTRN Stock News HeadlinesJuly 18, 2024 | americanbankingnews.comCASI Pharmaceuticals (NASDAQ:CASI) versus Lantern Pharma (NASDAQ:LTRN) Financial ComparisonJune 12, 2024 | businesswire.comLantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 23, 2024 | investorplace.comThe 3 Best Machine Learning Stocks to Quadruple Your Money by 2035May 14, 2024 | finance.yahoo.comLTRN: Expanding Horizons into AsiaMay 9, 2024 | businesswire.comLantern Pharma Reports First Quarter 2024 Financial Results and Business HighlightsMay 6, 2024 | businesswire.comOregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer MetabolismMay 2, 2024 | businesswire.comLantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ETJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 1, 2024 | investorplace.com3 Machine Learning Stocks with the Potential to Make You an Overnight MillionaireApril 25, 2024 | markets.businessinsider.comH.C. Wainwright Keeps Their Hold Rating on Lantern Pharma (LTRN)April 24, 2024 | finance.yahoo.comLantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug DevelopmentApril 24, 2024 | businesswire.comLantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug DevelopmentApril 22, 2024 | businesswire.comLantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and TaiwanApril 17, 2024 | finance.yahoo.comLantern Pharma Inc. (LTRN)April 13, 2024 | morningstar.comLantern Pharma Inc Ordinary SharesApril 10, 2024 | investing.comLantern Pharma Inc (LTRN)March 20, 2024 | seekingalpha.comLantern Pharma Inc. (LTRN) Q4 2023 Earnings Call TranscriptSee More Headlines Receive LTRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/27/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LTRN CUSIPN/A CIK1763950 Webwww.lanternpharma.com Phone972-277-1136FaxN/AEmployees21Year Founded2013Profitability EPS (Most Recent Fiscal Year)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-41.17% Return on Assets-38.41% Debt Debt-to-Equity RatioN/A Current Ratio9.99 Quick Ratio9.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.76 per share Price / Book1.22Miscellaneous Outstanding Shares10,760,000Free Float10,014,000Market Cap$49.28 million OptionableOptionable Beta1.56 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Panna Sharma PH.D. (Age 53)President, CEO & Director Comp: $684.38kMr. David R. Margrave (Age 63)CFO & Secretary Comp: $442.68kDr. Kishor Gopaldas Bhatia Ph.D. (Age 69)Chief Scientific Officer & Scientific Consultant Comp: $283.24kNicole LeberInvestor Relations Associate, Finance & Administrative CoordinatorDr. Peter L. Nara D.V.M.M.S., Ph.D., Co-Founder & AdvisorMr. Ernest Kitt B.S.M.S, Head of Clinical OperationsMore ExecutivesKey CompetitorsLeap TherapeuticsNASDAQ:LPTXBioXcel TherapeuticsNASDAQ:BTAIProPhase LabsNASDAQ:PRPHGritstone bioNASDAQ:GRTSVentyx BiosciencesNASDAQ:VTYXView All CompetitorsInsiders & InstitutionsWestside Investment Management Inc.Bought 11,500 shares on 7/17/2024Ownership: 0.107%Aaron G.L. FletcherSold 10,000 sharesTotal: $62,500.00 ($6.25/share)CM Management LLCSold 15,000 shares on 5/14/2024Ownership: 0.604%Tocqueville Asset Management L.P.Bought 19,000 shares on 5/10/2024Ownership: 0.177%Aaron G.L. FletcherSold 74,297 sharesTotal: $360,340.45 ($4.85/share)View All Insider TransactionsView All Institutional Transactions LTRN Stock Analysis - Frequently Asked Questions How have LTRN shares performed this year? Lantern Pharma's stock was trading at $4.28 on January 1st, 2024. Since then, LTRN shares have increased by 7.0% and is now trading at $4.58. View the best growth stocks for 2024 here. How were Lantern Pharma's earnings last quarter? Lantern Pharma Inc. (NASDAQ:LTRN) released its earnings results on Thursday, May, 9th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by $0.08. When did Lantern Pharma IPO? Lantern Pharma (LTRN) raised $26 million in an IPO on Thursday, June 11th 2020. The company issued 1,600,000 shares at $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers. Who are Lantern Pharma's major shareholders? Top institutional investors of Lantern Pharma include Westside Investment Management Inc. (0.11%). Insiders that own company stock include Leslie W Kreis and Aaron GL Fletcher. View institutional ownership trends. How do I buy shares of Lantern Pharma? Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Lantern Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lantern Pharma investors own include Applied Materials (AMAT), ARK Next Generation Internation ETF (ARKW), Conagra Brands (CAG), FedEx (FDX), Lowe's Companies (LOW), PayPal (PYPL) and This page (NASDAQ:LTRN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.